T-cell receptor Vgamma9-Vdelta2 (TCR Vγ9Vδ2)

The T-cell receptor Vgamma9-Vdelta2 is a heterodimeric receptor expressed on a major subset of human γδ T cells, predominantly in peripheral blood[12][5][6]. It is composed of a Vγ9 chain and a Vδ2 chain, forming the antigen-binding site. This receptor is unique in recognizing non-peptidic phosphoantigens—metabolites produced by microbes and stressed or transformed (tumor) cells—independently of classical MHC presentation[8][1][3]. Upon ligand recognition, often involving BTN3A1/BTN2A1 molecules on target cells, Vγ9Vδ2 T cells become potently cytotoxic, secrete key cytokines (e.g., IFN-γ, TNF-α), and can act as antigen-presenting cells to help initiate αβ T cell immunity[4][2]. Because of these properties, TCR Vγ9Vδ2 is an attractive target for immunotherapies against cancer and infection. Therapeutic interventions aim to expand or activate Vγ9Vδ2 T cells, using agents such as aminobisphosphonates or synthetic phosphoantigens. Safety challenges primarily relate to systemic activation risks, including cytokine release[2].

Other names

Vgamma9Vdelta2 T cell receptorVγ9Vδ2 TCRγδ T cell receptor Vγ9Vδ2Phosphoantigen receptor (context-dependent, less common)

Activation of Vγ9Vδ2 T cells by phosphoantigen presentation (through butyrophilin family members, especially BTN3A1/BTN2A1); Induction of cytotoxic response and cytokine secretion; Immunomodulation (drugs enhancing γδ T cell expansion/activation via TCR engagement)